Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $14.95, but opened at $15.42. HUTCHMED shares last traded at $15.75, with a volume of 9,897 shares trading hands.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Friday.
Get Our Latest Stock Analysis on HUTCHMED
HUTCHMED Trading Down 7.1 %
The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The stock's 50-day simple moving average is $14.69 and its two-hundred day simple moving average is $16.49.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio grew its holdings in shares of HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after purchasing an additional 899 shares during the last quarter. Summit Trail Advisors LLC grew its holdings in shares of HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after purchasing an additional 1,647 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after purchasing an additional 1,799 shares during the last quarter. Barclays PLC grew its holdings in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after purchasing an additional 2,255 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after purchasing an additional 3,078 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
